Biocept Inc (NASDAQ:BIOC) saw an uptick in trading volume on Tuesday . 3,128,144 shares were traded during trading, an increase of 260% from the previous session’s volume of 868,607 shares.The stock last traded at $0.72 and had previously closed at $0.72.

A number of research firms have recently weighed in on BIOC. ValuEngine raised Biocept from a “strong sell” rating to a “sell” rating in a research note on Monday, October 16th. Zacks Investment Research lowered Biocept from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $1.50 price target (down previously from $2.50) on shares of Biocept in a research note on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Biocept currently has a consensus rating of “Hold” and a consensus price target of $2.25.

The stock has a market capitalization of $21.86, a P/E ratio of -0.81 and a beta of 2.77. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.41 and a quick ratio of 1.27.

An institutional investor recently raised its position in Biocept stock. Vanguard Group Inc. boosted its position in Biocept Inc (NASDAQ:BIOC) by 9.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 764,351 shares of the medical research company’s stock after purchasing an additional 66,746 shares during the quarter. Vanguard Group Inc. owned approximately 2.87% of Biocept worth $1,048,000 at the end of the most recent quarter. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at

Biocept Company Profile

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.